Emerging studies suggest this peptide, a dual activator targeting both incretin and glucose-dependent insulinotropic polypeptide , may offer a promising advancement for obesity management . Initial patient trials have demonstrated considerable losses in visceral fat , conceivably surpassing current body composition treatments. Despite this, additio